nodes	percent_of_prediction	percent_of_DWPC	metapath
Celecoxib—ABCC4—Methotrexate—testicular cancer	0.0763	0.183	CbGbCtD
Celecoxib—PTGS2—Cisplatin—testicular cancer	0.0691	0.166	CbGbCtD
Celecoxib—PTGS2—Etoposide—testicular cancer	0.0679	0.163	CbGbCtD
Celecoxib—CYP2C9—Ifosfamide—testicular cancer	0.0483	0.116	CbGbCtD
Celecoxib—ALB—Methotrexate—testicular cancer	0.0283	0.0679	CbGbCtD
Celecoxib—CYP3A4—Ifosfamide—testicular cancer	0.0281	0.0674	CbGbCtD
Celecoxib—CYP2C9—Cisplatin—testicular cancer	0.0235	0.0564	CbGbCtD
Celecoxib—CYP2D6—Vinblastine—testicular cancer	0.0234	0.0562	CbGbCtD
Celecoxib—CYP3A4—Vinblastine—testicular cancer	0.0149	0.0357	CbGbCtD
Celecoxib—CYP2D6—Doxorubicin—testicular cancer	0.0144	0.0345	CbGbCtD
Celecoxib—CYP3A4—Etoposide—testicular cancer	0.0134	0.0322	CbGbCtD
Celecoxib—PDPK1—embryo—testicular cancer	0.0093	0.121	CbGeAlD
Celecoxib—CYP3A4—Doxorubicin—testicular cancer	0.00915	0.022	CbGbCtD
Celecoxib—PDPK1—gonad—testicular cancer	0.00631	0.0822	CbGeAlD
Celecoxib—PDPK1—FCERI mediated NF-kB activation—BCL10—testicular cancer	0.00597	0.0461	CbGpPWpGaD
Celecoxib—PDPK1—female gonad—testicular cancer	0.00513	0.0668	CbGeAlD
Celecoxib—MAPK14—embryo—testicular cancer	0.00497	0.0648	CbGeAlD
Celecoxib—PDPK1—testis—testicular cancer	0.00455	0.0593	CbGeAlD
Celecoxib—CA14—seminal vesicle—testicular cancer	0.00454	0.0592	CbGeAlD
Celecoxib—PDPK1—Downstream TCR signaling—BCL10—testicular cancer	0.00376	0.029	CbGpPWpGaD
Celecoxib—PDPK1—lymph node—testicular cancer	0.0033	0.0429	CbGeAlD
Celecoxib—PDPK1—TCR signaling in naïve CD8+ T cells—BCL10—testicular cancer	0.00306	0.0237	CbGpPWpGaD
Celecoxib—PDPK1—TCR signaling—BCL10—testicular cancer	0.00281	0.0217	CbGpPWpGaD
Celecoxib—MAPK14—female gonad—testicular cancer	0.00274	0.0357	CbGeAlD
Celecoxib—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—testicular cancer	0.00265	0.0204	CbGpPWpGaD
Celecoxib—PDPK1—TCR signaling in naïve CD4+ T cells—BCL10—testicular cancer	0.00257	0.0198	CbGpPWpGaD
Celecoxib—PDPK1—BCR signaling pathway—BCL10—testicular cancer	0.00254	0.0196	CbGpPWpGaD
Celecoxib—CA9—testis—testicular cancer	0.00249	0.0325	CbGeAlD
Celecoxib—MAPK14—testis—testicular cancer	0.00243	0.0317	CbGeAlD
Celecoxib—CA5B—gonad—testicular cancer	0.0023	0.0299	CbGeAlD
Celecoxib—ABCC4—Ectoderm Differentiation—TFAP2C—testicular cancer	0.00228	0.0176	CbGpPWpGaD
Celecoxib—CA4—seminal vesicle—testicular cancer	0.00219	0.0286	CbGeAlD
Celecoxib—PDPK1—TCR Signaling Pathway—BCL10—testicular cancer	0.002	0.0155	CbGpPWpGaD
Celecoxib—ABCC4—NRF2 pathway—SLC2A6—testicular cancer	0.002	0.0154	CbGpPWpGaD
Celecoxib—CA2—embryo—testicular cancer	0.00194	0.0252	CbGeAlD
Celecoxib—PDPK1—Signaling events mediated by Stem cell factor receptor (c-Kit)—KITLG—testicular cancer	0.0019	0.0147	CbGpPWpGaD
Celecoxib—PDPK1—B Cell Receptor Signaling Pathway—BCL10—testicular cancer	0.00189	0.0146	CbGpPWpGaD
Celecoxib—CA2—seminal vesicle—testicular cancer	0.00182	0.0237	CbGeAlD
Celecoxib—MAPK14—lymph node—testicular cancer	0.00176	0.023	CbGeAlD
Celecoxib—CA5B—testis—testicular cancer	0.00166	0.0216	CbGeAlD
Celecoxib—PDPK1—PI3K Cascade—STK11—testicular cancer	0.00164	0.0126	CbGpPWpGaD
Celecoxib—PTGS2—embryo—testicular cancer	0.00143	0.0186	CbGeAlD
Celecoxib—ABCC4—female gonad—testicular cancer	0.0014	0.0183	CbGeAlD
Celecoxib—PDPK1—IRS-mediated signalling—STK11—testicular cancer	0.00137	0.0106	CbGpPWpGaD
Celecoxib—PDPK1—FGF signaling pathway—FGFR3—testicular cancer	0.00135	0.0104	CbGpPWpGaD
Celecoxib—PTGS2—seminal vesicle—testicular cancer	0.00134	0.0175	CbGeAlD
Celecoxib—PDPK1—IRS-related events—STK11—testicular cancer	0.00133	0.0103	CbGpPWpGaD
Celecoxib—MAPK14—BCR signaling pathway—BCL10—testicular cancer	0.00132	0.0102	CbGpPWpGaD
Celecoxib—PDPK1—IRS-related events triggered by IGF1R—STK11—testicular cancer	0.00132	0.0102	CbGpPWpGaD
Celecoxib—PDPK1—Signaling events mediated by Stem cell factor receptor (c-Kit)—KIT—testicular cancer	0.0013	0.01	CbGpPWpGaD
Celecoxib—CA4—female gonad—testicular cancer	0.00129	0.0168	CbGeAlD
Celecoxib—ALB—testis—testicular cancer	0.00128	0.0167	CbGeAlD
Celecoxib—PDPK1—IGF1R signaling cascade—STK11—testicular cancer	0.00128	0.00992	CbGpPWpGaD
Celecoxib—PDPK1—Insulin receptor signalling cascade—STK11—testicular cancer	0.00128	0.00992	CbGpPWpGaD
Celecoxib—PDPK1—Constitutive PI3K/AKT Signaling in Cancer—KITLG—testicular cancer	0.00125	0.00968	CbGpPWpGaD
Celecoxib—ABCC4—testis—testicular cancer	0.00124	0.0162	CbGeAlD
Celecoxib—PDPK1—Downstream signaling events of B Cell Receptor (BCR)—BCL10—testicular cancer	0.00122	0.00944	CbGpPWpGaD
Celecoxib—CA5B—lymph node—testicular cancer	0.0012	0.0156	CbGeAlD
Celecoxib—PDPK1—Fc epsilon receptor (FCERI) signaling—BCL10—testicular cancer	0.00117	0.00901	CbGpPWpGaD
Celecoxib—CA4—testis—testicular cancer	0.00114	0.0149	CbGeAlD
Celecoxib—PDPK1—PI-3K cascade—KITLG—testicular cancer	0.00113	0.00872	CbGpPWpGaD
Celecoxib—PDPK1—PI3K Cascade—FGFR3—testicular cancer	0.00112	0.00868	CbGpPWpGaD
Celecoxib—PDPK1—PI3K/AKT activation—KITLG—testicular cancer	0.0011	0.00851	CbGpPWpGaD
Celecoxib—PDPK1—GAB1 signalosome—KITLG—testicular cancer	0.00109	0.00845	CbGpPWpGaD
Celecoxib—PDPK1—B Cell Activation—BCL10—testicular cancer	0.00108	0.00834	CbGpPWpGaD
Celecoxib—PDPK1—Role of LAT2/NTAL/LAB on calcium mobilization—KITLG—testicular cancer	0.00107	0.00825	CbGpPWpGaD
Celecoxib—CA2—female gonad—testicular cancer	0.00107	0.0139	CbGeAlD
Celecoxib—PDPK1—Signaling by Insulin receptor—STK11—testicular cancer	0.00107	0.00824	CbGpPWpGaD
Celecoxib—ORM1—lymph node—testicular cancer	0.00106	0.0138	CbGeAlD
Celecoxib—MAPK14—TCR Signaling Pathway—BCL10—testicular cancer	0.00104	0.00805	CbGpPWpGaD
Celecoxib—PTGS2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.00102	0.00789	CbGpPWpGaD
Celecoxib—MAPK14—B Cell Receptor Signaling Pathway—BCL10—testicular cancer	0.000981	0.00758	CbGpPWpGaD
Celecoxib—PTGS2—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000955	0.00738	CbGpPWpGaD
Celecoxib—CA2—testis—testicular cancer	0.000948	0.0123	CbGeAlD
Celecoxib—PDPK1—IRS-mediated signalling—FGFR3—testicular cancer	0.000941	0.00726	CbGpPWpGaD
Celecoxib—PDPK1—Constitutive PI3K/AKT Signaling in Cancer—FGFR3—testicular cancer	0.000932	0.0072	CbGpPWpGaD
Celecoxib—ALB—lymph node—testicular cancer	0.000931	0.0121	CbGeAlD
Celecoxib—PDPK1—IRS-related events—FGFR3—testicular cancer	0.000915	0.00707	CbGpPWpGaD
Celecoxib—PDPK1—IRS-related events triggered by IGF1R—FGFR3—testicular cancer	0.000907	0.007	CbGpPWpGaD
Celecoxib—ABCC4—lymph node—testicular cancer	0.000901	0.0117	CbGeAlD
Celecoxib—PDPK1—IGF1R signaling cascade—FGFR3—testicular cancer	0.000883	0.00682	CbGpPWpGaD
Celecoxib—PDPK1—Insulin receptor signalling cascade—FGFR3—testicular cancer	0.000883	0.00682	CbGpPWpGaD
Celecoxib—MAPK14—Kit receptor signaling pathway—KITLG—testicular cancer	0.000881	0.0068	CbGpPWpGaD
Celecoxib—PDPK1—Constitutive PI3K/AKT Signaling in Cancer—KIT—testicular cancer	0.000856	0.00661	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by SCF-KIT—KITLG—testicular cancer	0.000844	0.00652	CbGpPWpGaD
Celecoxib—PDPK1—PI-3K cascade—FGFR3—testicular cancer	0.000839	0.00648	CbGpPWpGaD
Celecoxib—CA4—lymph node—testicular cancer	0.000828	0.0108	CbGeAlD
Celecoxib—PDPK1—PI3K/AKT activation—FGFR3—testicular cancer	0.000819	0.00633	CbGpPWpGaD
Celecoxib—PDPK1—GAB1 signalosome—FGFR3—testicular cancer	0.000813	0.00628	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—PRDM14—testicular cancer	0.000809	0.00625	CbGpPWpGaD
Celecoxib—PDPK1—Downstream signaling of activated FGFR—KITLG—testicular cancer	0.000808	0.00624	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by ERBB4—KITLG—testicular cancer	0.000795	0.00614	CbGpPWpGaD
Celecoxib—PDPK1—Role of LAT2/NTAL/LAB on calcium mobilization—FGFR3—testicular cancer	0.000794	0.00613	CbGpPWpGaD
Celecoxib—PTGS2—female gonad—testicular cancer	0.000789	0.0103	CbGeAlD
Celecoxib—PDPK1—PI-3K cascade—KIT—testicular cancer	0.000771	0.00595	CbGpPWpGaD
Celecoxib—PDPK1—Downstream signal transduction—KITLG—testicular cancer	0.000759	0.00586	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by FGFR—KITLG—testicular cancer	0.000755	0.00583	CbGpPWpGaD
Celecoxib—PDPK1—PI3K/AKT activation—KIT—testicular cancer	0.000752	0.00581	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by ERBB2—KITLG—testicular cancer	0.000752	0.00581	CbGpPWpGaD
Celecoxib—PDPK1—DAP12 signaling—KITLG—testicular cancer	0.000748	0.00578	CbGpPWpGaD
Celecoxib—PDPK1—GAB1 signalosome—KIT—testicular cancer	0.000746	0.00576	CbGpPWpGaD
Celecoxib—PDPK1—Downstream signaling events of B Cell Receptor (BCR)—KITLG—testicular cancer	0.000737	0.00569	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by Insulin receptor—FGFR3—testicular cancer	0.000733	0.00566	CbGpPWpGaD
Celecoxib—PDPK1—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—testicular cancer	0.000729	0.00563	CbGpPWpGaD
Celecoxib—PDPK1—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	0.000704	0.00544	CbGpPWpGaD
Celecoxib—PDPK1—DAP12 interactions—KITLG—testicular cancer	0.000704	0.00544	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by FGFR in disease—KITLG—testicular cancer	0.000704	0.00544	CbGpPWpGaD
Celecoxib—MAPK14—FGF signaling pathway—FGFR3—testicular cancer	0.000703	0.00543	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by EGFR—KITLG—testicular cancer	0.000697	0.00539	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by EGFR in Cancer—KITLG—testicular cancer	0.000691	0.00534	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by PDGF—KITLG—testicular cancer	0.000688	0.00532	CbGpPWpGaD
Celecoxib—CA2—lymph node—testicular cancer	0.000687	0.00895	CbGeAlD
Celecoxib—CYP2D6—female gonad—testicular cancer	0.000678	0.00884	CbGeAlD
Celecoxib—PTGS2—C-MYB transcription factor network—MAD1L1—testicular cancer	0.000661	0.00511	CbGpPWpGaD
Celecoxib—MAPK14—Cardiac Progenitor Differentiation—KIT—testicular cancer	0.000655	0.00506	CbGpPWpGaD
Celecoxib—PDPK1—GPCR downstream signaling—INSL3—testicular cancer	0.000652	0.00503	CbGpPWpGaD
Celecoxib—PDPK1—B Cell Activation—KITLG—testicular cancer	0.000651	0.00503	CbGpPWpGaD
Celecoxib—ABCC4—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00064	0.00494	CbGpPWpGaD
Celecoxib—CYP2C9—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000633	0.00489	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by SCF-KIT—FGFR3—testicular cancer	0.000627	0.00485	CbGpPWpGaD
Celecoxib—PDPK1—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.000623	0.00481	CbGpPWpGaD
Celecoxib—MAPK14—Angiopoietin receptor Tie2-mediated signaling—MMP2—testicular cancer	0.000608	0.0047	CbGpPWpGaD
Celecoxib—CYP2D6—testis—testicular cancer	0.000602	0.00784	CbGeAlD
Celecoxib—MAPK14—Kit receptor signaling pathway—KIT—testicular cancer	0.000601	0.00464	CbGpPWpGaD
Celecoxib—PDPK1—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.0006	0.00464	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—INSL3—testicular cancer	0.000592	0.00457	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by ERBB4—FGFR3—testicular cancer	0.000591	0.00456	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by SCF-KIT—KIT—testicular cancer	0.000576	0.00445	CbGpPWpGaD
Celecoxib—ALB—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00057	0.0044	CbGpPWpGaD
Celecoxib—PDPK1—Downstream signal transduction—FGFR3—testicular cancer	0.000564	0.00436	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by FGFR—FGFR3—testicular cancer	0.000561	0.00434	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by ERBB2—FGFR3—testicular cancer	0.000559	0.00431	CbGpPWpGaD
Celecoxib—PDPK1—DAP12 signaling—FGFR3—testicular cancer	0.000556	0.00429	CbGpPWpGaD
Celecoxib—PDPK1—Downstream signaling of activated FGFR—KIT—testicular cancer	0.000551	0.00426	CbGpPWpGaD
Celecoxib—PDPK1—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	0.000548	0.00423	CbGpPWpGaD
Celecoxib—MAPK14—Oxidative Stress Induced Senescence—H2AFZ—testicular cancer	0.000546	0.00422	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by ERBB4—KIT—testicular cancer	0.000542	0.00419	CbGpPWpGaD
Celecoxib—MAPK14—ATF-2 transcription factor network—MMP2—testicular cancer	0.000533	0.00411	CbGpPWpGaD
Celecoxib—PDPK1—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.000523	0.00404	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by FGFR in disease—FGFR3—testicular cancer	0.000523	0.00404	CbGpPWpGaD
Celecoxib—PDPK1—DAP12 interactions—FGFR3—testicular cancer	0.000523	0.00404	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by EGFR—FGFR3—testicular cancer	0.000518	0.004	CbGpPWpGaD
Celecoxib—PDPK1—Downstream signal transduction—KIT—testicular cancer	0.000518	0.004	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by FGFR—KIT—testicular cancer	0.000515	0.00398	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.000514	0.00397	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by ERBB2—KIT—testicular cancer	0.000513	0.00396	CbGpPWpGaD
Celecoxib—MAPK14—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000512	0.00395	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by PDGF—FGFR3—testicular cancer	0.000512	0.00395	CbGpPWpGaD
Celecoxib—PDPK1—DAP12 signaling—KIT—testicular cancer	0.00051	0.00394	CbGpPWpGaD
Celecoxib—PTGS2—lymph node—testicular cancer	0.000507	0.00661	CbGeAlD
Celecoxib—PDPK1—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	0.000503	0.00389	CbGpPWpGaD
Celecoxib—MAPK14—AGE/RAGE pathway—MMP2—testicular cancer	0.000487	0.00376	CbGpPWpGaD
Celecoxib—PDPK1—B Cell Activation—FGFR3—testicular cancer	0.000484	0.00374	CbGpPWpGaD
Celecoxib—PDPK1—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.00048	0.00371	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by FGFR in disease—KIT—testicular cancer	0.00048	0.00371	CbGpPWpGaD
Celecoxib—PDPK1—DAP12 interactions—KIT—testicular cancer	0.00048	0.00371	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by NGF—KITLG—testicular cancer	0.000479	0.0037	CbGpPWpGaD
Celecoxib—CA9—Cellular responses to stress—H2AFZ—testicular cancer	0.000479	0.0037	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by EGFR—KIT—testicular cancer	0.000476	0.00368	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by EGFR in Cancer—KIT—testicular cancer	0.000472	0.00364	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by PDGF—KIT—testicular cancer	0.00047	0.00363	CbGpPWpGaD
Celecoxib—PDPK1—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000463	0.00358	CbGpPWpGaD
Celecoxib—PTGS2—C-MYB transcription factor network—H2AFZ—testicular cancer	0.000461	0.00356	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—BCL10—testicular cancer	0.000453	0.0035	CbGpPWpGaD
Celecoxib—PDPK1—B Cell Activation—KIT—testicular cancer	0.000444	0.00343	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—BCL10—testicular cancer	0.000435	0.00336	CbGpPWpGaD
Celecoxib—PDPK1—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000425	0.00328	CbGpPWpGaD
Celecoxib—PTGS2—C-MYB transcription factor network—KITLG—testicular cancer	0.000424	0.00328	CbGpPWpGaD
Celecoxib—MAPK14—Cellular Senescence—H2AFZ—testicular cancer	0.000382	0.00295	CbGpPWpGaD
Celecoxib—MAPK14—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000372	0.00287	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by NGF—FGFR3—testicular cancer	0.000356	0.00275	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—INSL3—testicular cancer	0.00035	0.0027	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by NGF—KIT—testicular cancer	0.000327	0.00253	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000327	0.00253	CbGpPWpGaD
Celecoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.000324	0.0025	CbGpPWpGaD
Celecoxib—CA14—Metabolism—HPGDS—testicular cancer	0.00029	0.00224	CbGpPWpGaD
Celecoxib—PTGS2—C-MYB transcription factor network—KIT—testicular cancer	0.000289	0.00224	CbGpPWpGaD
Celecoxib—ALB—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000289	0.00224	CbGpPWpGaD
Celecoxib—MAPK14—Cellular responses to stress—H2AFZ—testicular cancer	0.000289	0.00223	CbGpPWpGaD
Celecoxib—CA6—Metabolism—HPGDS—testicular cancer	0.000283	0.00219	CbGpPWpGaD
Celecoxib—CA5A—Metabolism—HPGDS—testicular cancer	0.000283	0.00219	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—KITLG—testicular cancer	0.000273	0.00211	CbGpPWpGaD
Celecoxib—CA5B—Metabolism—HPGDS—testicular cancer	0.000264	0.00204	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—BCL10—testicular cancer	0.000264	0.00204	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—KITLG—testicular cancer	0.000263	0.00203	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—DNMT3L—testicular cancer	0.000256	0.00197	CbGpPWpGaD
Celecoxib—MAPK14—Signaling by NGF—KITLG—testicular cancer	0.000249	0.00192	CbGpPWpGaD
Celecoxib—CA12—Metabolism—HPGDS—testicular cancer	0.000245	0.00189	CbGpPWpGaD
Celecoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000241	0.00186	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000238	0.00183	CbGpPWpGaD
Celecoxib—CYP2D6—Biological oxidations—HPGDS—testicular cancer	0.000238	0.00183	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—BCL10—testicular cancer	0.000236	0.00182	CbGpPWpGaD
Celecoxib—CYP2C9—Biological oxidations—HPGDS—testicular cancer	0.000235	0.00182	CbGpPWpGaD
Celecoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.000221	0.00171	CbGpPWpGaD
Celecoxib—CA14—Metabolism—STK11—testicular cancer	0.000211	0.00163	CbGpPWpGaD
Celecoxib—CA5A—Metabolism—STK11—testicular cancer	0.000206	0.00159	CbGpPWpGaD
Celecoxib—CA6—Metabolism—STK11—testicular cancer	0.000206	0.00159	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—FGFR3—testicular cancer	0.000203	0.00157	CbGpPWpGaD
Celecoxib—Hyperglycaemia—Doxorubicin—testicular cancer	0.000197	0.000523	CcSEcCtD
Celecoxib—Nausea—Dactinomycin—testicular cancer	0.000197	0.000522	CcSEcCtD
Celecoxib—Agranulocytosis—Epirubicin—testicular cancer	0.000197	0.000521	CcSEcCtD
Celecoxib—Pneumonia—Doxorubicin—testicular cancer	0.000196	0.00052	CcSEcCtD
Celecoxib—Gastrointestinal pain—Etoposide—testicular cancer	0.000196	0.00052	CcSEcCtD
Celecoxib—CA4—Metabolism—HPGDS—testicular cancer	0.000195	0.00151	CbGpPWpGaD
Celecoxib—PDPK1—Adaptive Immune System—FGFR3—testicular cancer	0.000195	0.00151	CbGpPWpGaD
Celecoxib—Infestation—Doxorubicin—testicular cancer	0.000195	0.000517	CcSEcCtD
Celecoxib—Infestation NOS—Doxorubicin—testicular cancer	0.000195	0.000517	CcSEcCtD
Celecoxib—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000193	0.000512	CcSEcCtD
Celecoxib—Vomiting—Ifosfamide—testicular cancer	0.000193	0.000512	CcSEcCtD
Celecoxib—Hypersensitivity—Cisplatin—testicular cancer	0.000193	0.000511	CcSEcCtD
Celecoxib—CA5B—Metabolism—STK11—testicular cancer	0.000192	0.00148	CbGpPWpGaD
Celecoxib—Rash—Ifosfamide—testicular cancer	0.000191	0.000507	CcSEcCtD
Celecoxib—Dermatitis—Ifosfamide—testicular cancer	0.000191	0.000507	CcSEcCtD
Celecoxib—Erythema multiforme—Methotrexate—testicular cancer	0.000191	0.000507	CcSEcCtD
Celecoxib—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000191	0.000507	CcSEcCtD
Celecoxib—Urticaria—Etoposide—testicular cancer	0.00019	0.000505	CcSEcCtD
Celecoxib—Haemoglobin—Epirubicin—testicular cancer	0.00019	0.000504	CcSEcCtD
Celecoxib—Stomatitis—Doxorubicin—testicular cancer	0.00019	0.000504	CcSEcCtD
Celecoxib—Jaundice—Doxorubicin—testicular cancer	0.00019	0.000504	CcSEcCtD
Celecoxib—Rhinitis—Epirubicin—testicular cancer	0.00019	0.000503	CcSEcCtD
Celecoxib—Body temperature increased—Etoposide—testicular cancer	0.000189	0.000502	CcSEcCtD
Celecoxib—Abdominal pain—Etoposide—testicular cancer	0.000189	0.000502	CcSEcCtD
Celecoxib—Conjunctivitis—Doxorubicin—testicular cancer	0.000189	0.000502	CcSEcCtD
Celecoxib—Urinary tract infection—Doxorubicin—testicular cancer	0.000189	0.000502	CcSEcCtD
Celecoxib—Haemorrhage—Epirubicin—testicular cancer	0.000189	0.000501	CcSEcCtD
Celecoxib—Hepatitis—Epirubicin—testicular cancer	0.000189	0.000501	CcSEcCtD
Celecoxib—Eye disorder—Methotrexate—testicular cancer	0.000189	0.000501	CcSEcCtD
Celecoxib—Tinnitus—Methotrexate—testicular cancer	0.000188	0.0005	CcSEcCtD
Celecoxib—Hypoaesthesia—Epirubicin—testicular cancer	0.000188	0.000499	CcSEcCtD
Celecoxib—Asthenia—Cisplatin—testicular cancer	0.000188	0.000498	CcSEcCtD
Celecoxib—Pharyngitis—Epirubicin—testicular cancer	0.000188	0.000498	CcSEcCtD
Celecoxib—Cardiac disorder—Methotrexate—testicular cancer	0.000188	0.000497	CcSEcCtD
Celecoxib—CA2—Metabolism—HPGDS—testicular cancer	0.000187	0.00145	CbGpPWpGaD
Celecoxib—Urinary tract disorder—Epirubicin—testicular cancer	0.000187	0.000495	CcSEcCtD
Celecoxib—PDPK1—Innate Immune System—KIT—testicular cancer	0.000187	0.00144	CbGpPWpGaD
Celecoxib—Oedema peripheral—Epirubicin—testicular cancer	0.000186	0.000494	CcSEcCtD
Celecoxib—Haematuria—Doxorubicin—testicular cancer	0.000186	0.000493	CcSEcCtD
Celecoxib—Connective tissue disorder—Epirubicin—testicular cancer	0.000186	0.000493	CcSEcCtD
Celecoxib—Urethral disorder—Epirubicin—testicular cancer	0.000185	0.000492	CcSEcCtD
Celecoxib—MAPK14—Signaling by NGF—FGFR3—testicular cancer	0.000185	0.00143	CbGpPWpGaD
Celecoxib—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000184	0.000489	CcSEcCtD
Celecoxib—Epistaxis—Doxorubicin—testicular cancer	0.000184	0.000487	CcSEcCtD
Celecoxib—Angiopathy—Methotrexate—testicular cancer	0.000183	0.000486	CcSEcCtD
Celecoxib—Sinusitis—Doxorubicin—testicular cancer	0.000183	0.000485	CcSEcCtD
Celecoxib—Immune system disorder—Methotrexate—testicular cancer	0.000182	0.000484	CcSEcCtD
Celecoxib—Mediastinal disorder—Methotrexate—testicular cancer	0.000182	0.000483	CcSEcCtD
Celecoxib—Agranulocytosis—Doxorubicin—testicular cancer	0.000182	0.000482	CcSEcCtD
Celecoxib—MAPK14—Signaling Pathways—INSL3—testicular cancer	0.000182	0.0014	CbGpPWpGaD
Celecoxib—Nausea—Ifosfamide—testicular cancer	0.00018	0.000478	CcSEcCtD
Celecoxib—PDPK1—Adaptive Immune System—KIT—testicular cancer	0.000179	0.00138	CbGpPWpGaD
Celecoxib—Diarrhoea—Cisplatin—testicular cancer	0.000179	0.000475	CcSEcCtD
Celecoxib—Erythema multiforme—Epirubicin—testicular cancer	0.000179	0.000474	CcSEcCtD
Celecoxib—Alopecia—Methotrexate—testicular cancer	0.000179	0.000473	CcSEcCtD
Celecoxib—CA12—Metabolism—STK11—testicular cancer	0.000178	0.00137	CbGpPWpGaD
Celecoxib—Mental disorder—Methotrexate—testicular cancer	0.000177	0.000469	CcSEcCtD
Celecoxib—Eye disorder—Epirubicin—testicular cancer	0.000177	0.000469	CcSEcCtD
Celecoxib—Hypersensitivity—Etoposide—testicular cancer	0.000177	0.000468	CcSEcCtD
Celecoxib—Tinnitus—Epirubicin—testicular cancer	0.000176	0.000468	CcSEcCtD
Celecoxib—Haemoglobin—Doxorubicin—testicular cancer	0.000176	0.000466	CcSEcCtD
Celecoxib—Cardiac disorder—Epirubicin—testicular cancer	0.000175	0.000465	CcSEcCtD
Celecoxib—Flushing—Epirubicin—testicular cancer	0.000175	0.000465	CcSEcCtD
Celecoxib—Rhinitis—Doxorubicin—testicular cancer	0.000175	0.000465	CcSEcCtD
Celecoxib—Haemorrhage—Doxorubicin—testicular cancer	0.000175	0.000464	CcSEcCtD
Celecoxib—Hepatitis—Doxorubicin—testicular cancer	0.000175	0.000464	CcSEcCtD
Celecoxib—Hypoaesthesia—Doxorubicin—testicular cancer	0.000174	0.000462	CcSEcCtD
Celecoxib—Pharyngitis—Doxorubicin—testicular cancer	0.000174	0.00046	CcSEcCtD
Celecoxib—Urinary tract disorder—Doxorubicin—testicular cancer	0.000173	0.000458	CcSEcCtD
Celecoxib—Oedema peripheral—Doxorubicin—testicular cancer	0.000172	0.000457	CcSEcCtD
Celecoxib—Dysgeusia—Methotrexate—testicular cancer	0.000172	0.000457	CcSEcCtD
Celecoxib—Asthenia—Etoposide—testicular cancer	0.000172	0.000456	CcSEcCtD
Celecoxib—Connective tissue disorder—Doxorubicin—testicular cancer	0.000172	0.000456	CcSEcCtD
Celecoxib—Angiopathy—Epirubicin—testicular cancer	0.000172	0.000455	CcSEcCtD
Celecoxib—Urethral disorder—Doxorubicin—testicular cancer	0.000171	0.000455	CcSEcCtD
Celecoxib—Immune system disorder—Epirubicin—testicular cancer	0.000171	0.000453	CcSEcCtD
Celecoxib—Mediastinal disorder—Epirubicin—testicular cancer	0.00017	0.000452	CcSEcCtD
Celecoxib—Back pain—Methotrexate—testicular cancer	0.00017	0.000451	CcSEcCtD
Celecoxib—MAPK14—Signaling by NGF—KIT—testicular cancer	0.00017	0.00131	CbGpPWpGaD
Celecoxib—Pruritus—Etoposide—testicular cancer	0.00017	0.00045	CcSEcCtD
Celecoxib—Arrhythmia—Epirubicin—testicular cancer	0.000169	0.000448	CcSEcCtD
Celecoxib—Alopecia—Epirubicin—testicular cancer	0.000167	0.000443	CcSEcCtD
Celecoxib—Vomiting—Cisplatin—testicular cancer	0.000166	0.000441	CcSEcCtD
Celecoxib—Vision blurred—Methotrexate—testicular cancer	0.000166	0.00044	CcSEcCtD
Celecoxib—Mental disorder—Epirubicin—testicular cancer	0.000166	0.000439	CcSEcCtD
Celecoxib—Erythema multiforme—Doxorubicin—testicular cancer	0.000165	0.000439	CcSEcCtD
Celecoxib—Rash—Cisplatin—testicular cancer	0.000165	0.000437	CcSEcCtD
Celecoxib—Dermatitis—Cisplatin—testicular cancer	0.000165	0.000437	CcSEcCtD
Celecoxib—Diarrhoea—Etoposide—testicular cancer	0.000164	0.000435	CcSEcCtD
Celecoxib—Eye disorder—Doxorubicin—testicular cancer	0.000163	0.000434	CcSEcCtD
Celecoxib—Tinnitus—Doxorubicin—testicular cancer	0.000163	0.000433	CcSEcCtD
Celecoxib—Anaemia—Methotrexate—testicular cancer	0.000163	0.000431	CcSEcCtD
Celecoxib—Cardiac disorder—Doxorubicin—testicular cancer	0.000162	0.000431	CcSEcCtD
Celecoxib—Flushing—Doxorubicin—testicular cancer	0.000162	0.000431	CcSEcCtD
Celecoxib—Flatulence—Epirubicin—testicular cancer	0.000162	0.00043	CcSEcCtD
Celecoxib—Tension—Epirubicin—testicular cancer	0.000162	0.000428	CcSEcCtD
Celecoxib—Dysgeusia—Epirubicin—testicular cancer	0.000161	0.000427	CcSEcCtD
Celecoxib—Nervousness—Epirubicin—testicular cancer	0.00016	0.000424	CcSEcCtD
Celecoxib—PDPK1—Disease—H2AFZ—testicular cancer	0.00016	0.00123	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—KITLG—testicular cancer	0.000159	0.00123	CbGpPWpGaD
Celecoxib—Back pain—Epirubicin—testicular cancer	0.000159	0.000422	CcSEcCtD
Celecoxib—Angiopathy—Doxorubicin—testicular cancer	0.000159	0.000421	CcSEcCtD
Celecoxib—Dizziness—Etoposide—testicular cancer	0.000158	0.00042	CcSEcCtD
Celecoxib—Muscle spasms—Epirubicin—testicular cancer	0.000158	0.00042	CcSEcCtD
Celecoxib—Immune system disorder—Doxorubicin—testicular cancer	0.000158	0.000419	CcSEcCtD
Celecoxib—Vertigo—Methotrexate—testicular cancer	0.000158	0.000419	CcSEcCtD
Celecoxib—CA9—Metabolism—HPGDS—testicular cancer	0.000158	0.00122	CbGpPWpGaD
Celecoxib—Mediastinal disorder—Doxorubicin—testicular cancer	0.000158	0.000418	CcSEcCtD
Celecoxib—Leukopenia—Methotrexate—testicular cancer	0.000157	0.000418	CcSEcCtD
Celecoxib—Arrhythmia—Doxorubicin—testicular cancer	0.000156	0.000414	CcSEcCtD
Celecoxib—Nausea—Cisplatin—testicular cancer	0.000155	0.000412	CcSEcCtD
Celecoxib—CYP3A4—Biological oxidations—HPGDS—testicular cancer	0.000155	0.0012	CbGpPWpGaD
Celecoxib—Vision blurred—Epirubicin—testicular cancer	0.000155	0.000411	CcSEcCtD
Celecoxib—Alopecia—Doxorubicin—testicular cancer	0.000155	0.00041	CcSEcCtD
Celecoxib—Cough—Methotrexate—testicular cancer	0.000153	0.000407	CcSEcCtD
Celecoxib—Mental disorder—Doxorubicin—testicular cancer	0.000153	0.000406	CcSEcCtD
Celecoxib—Vomiting—Etoposide—testicular cancer	0.000152	0.000404	CcSEcCtD
Celecoxib—Anaemia—Epirubicin—testicular cancer	0.000152	0.000403	CcSEcCtD
Celecoxib—Rash—Etoposide—testicular cancer	0.000151	0.000401	CcSEcCtD
Celecoxib—Dermatitis—Etoposide—testicular cancer	0.000151	0.0004	CcSEcCtD
Celecoxib—Headache—Etoposide—testicular cancer	0.00015	0.000398	CcSEcCtD
Celecoxib—Flatulence—Doxorubicin—testicular cancer	0.00015	0.000398	CcSEcCtD
Celecoxib—Myalgia—Methotrexate—testicular cancer	0.00015	0.000397	CcSEcCtD
Celecoxib—Arthralgia—Methotrexate—testicular cancer	0.00015	0.000397	CcSEcCtD
Celecoxib—Chest pain—Methotrexate—testicular cancer	0.00015	0.000397	CcSEcCtD
Celecoxib—Tension—Doxorubicin—testicular cancer	0.000149	0.000396	CcSEcCtD
Celecoxib—Dysgeusia—Doxorubicin—testicular cancer	0.000149	0.000396	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000149	0.000394	CcSEcCtD
Celecoxib—Nervousness—Doxorubicin—testicular cancer	0.000148	0.000392	CcSEcCtD
Celecoxib—Vertigo—Epirubicin—testicular cancer	0.000148	0.000392	CcSEcCtD
Celecoxib—Syncope—Epirubicin—testicular cancer	0.000148	0.000391	CcSEcCtD
Celecoxib—Leukopenia—Epirubicin—testicular cancer	0.000147	0.000391	CcSEcCtD
Celecoxib—Back pain—Doxorubicin—testicular cancer	0.000147	0.000391	CcSEcCtD
Celecoxib—PDPK1—Disease—KITLG—testicular cancer	0.000147	0.00114	CbGpPWpGaD
Celecoxib—Muscle spasms—Doxorubicin—testicular cancer	0.000146	0.000388	CcSEcCtD
Celecoxib—Palpitations—Epirubicin—testicular cancer	0.000145	0.000386	CcSEcCtD
Celecoxib—Confusional state—Methotrexate—testicular cancer	0.000145	0.000384	CcSEcCtD
Celecoxib—Loss of consciousness—Epirubicin—testicular cancer	0.000145	0.000384	CcSEcCtD
Celecoxib—Cough—Epirubicin—testicular cancer	0.000144	0.000381	CcSEcCtD
Celecoxib—Anaphylactic shock—Methotrexate—testicular cancer	0.000144	0.000381	CcSEcCtD
Celecoxib—Vision blurred—Doxorubicin—testicular cancer	0.000144	0.000381	CcSEcCtD
Celecoxib—Infection—Methotrexate—testicular cancer	0.000143	0.000378	CcSEcCtD
Celecoxib—Nausea—Etoposide—testicular cancer	0.000142	0.000378	CcSEcCtD
Celecoxib—MAPK14—Innate Immune System—KITLG—testicular cancer	0.000142	0.0011	CbGpPWpGaD
Celecoxib—Hypertension—Epirubicin—testicular cancer	0.000142	0.000377	CcSEcCtD
Celecoxib—CA4—Metabolism—STK11—testicular cancer	0.000142	0.0011	CbGpPWpGaD
Celecoxib—Nervous system disorder—Methotrexate—testicular cancer	0.000141	0.000373	CcSEcCtD
Celecoxib—Anaemia—Doxorubicin—testicular cancer	0.000141	0.000373	CcSEcCtD
Celecoxib—Thrombocytopenia—Methotrexate—testicular cancer	0.000141	0.000373	CcSEcCtD
Celecoxib—Arthralgia—Epirubicin—testicular cancer	0.00014	0.000372	CcSEcCtD
Celecoxib—Myalgia—Epirubicin—testicular cancer	0.00014	0.000372	CcSEcCtD
Celecoxib—Chest pain—Epirubicin—testicular cancer	0.00014	0.000372	CcSEcCtD
Celecoxib—Anxiety—Epirubicin—testicular cancer	0.00014	0.00037	CcSEcCtD
Celecoxib—Skin disorder—Methotrexate—testicular cancer	0.000139	0.00037	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000139	0.000369	CcSEcCtD
Celecoxib—Hyperhidrosis—Methotrexate—testicular cancer	0.000139	0.000368	CcSEcCtD
Celecoxib—MAPK14—Immune System—BCL10—testicular cancer	0.000137	0.00106	CbGpPWpGaD
Celecoxib—Dry mouth—Epirubicin—testicular cancer	0.000137	0.000363	CcSEcCtD
Celecoxib—Vertigo—Doxorubicin—testicular cancer	0.000137	0.000363	CcSEcCtD
Celecoxib—Anorexia—Methotrexate—testicular cancer	0.000137	0.000363	CcSEcCtD
Celecoxib—Syncope—Doxorubicin—testicular cancer	0.000137	0.000362	CcSEcCtD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000137	0.00105	CbGpPWpGaD
Celecoxib—Leukopenia—Doxorubicin—testicular cancer	0.000136	0.000362	CcSEcCtD
Celecoxib—CA2—Metabolism—STK11—testicular cancer	0.000136	0.00105	CbGpPWpGaD
Celecoxib—Confusional state—Epirubicin—testicular cancer	0.000135	0.000359	CcSEcCtD
Celecoxib—Palpitations—Doxorubicin—testicular cancer	0.000135	0.000357	CcSEcCtD
Celecoxib—Anaphylactic shock—Epirubicin—testicular cancer	0.000134	0.000356	CcSEcCtD
Celecoxib—Oedema—Epirubicin—testicular cancer	0.000134	0.000356	CcSEcCtD
Celecoxib—Loss of consciousness—Doxorubicin—testicular cancer	0.000134	0.000355	CcSEcCtD
Celecoxib—Infection—Epirubicin—testicular cancer	0.000133	0.000354	CcSEcCtD
Celecoxib—Cough—Doxorubicin—testicular cancer	0.000133	0.000352	CcSEcCtD
Celecoxib—Shock—Epirubicin—testicular cancer	0.000132	0.000351	CcSEcCtD
Celecoxib—Nervous system disorder—Epirubicin—testicular cancer	0.000132	0.000349	CcSEcCtD
Celecoxib—Thrombocytopenia—Epirubicin—testicular cancer	0.000132	0.000349	CcSEcCtD
Celecoxib—Hypertension—Doxorubicin—testicular cancer	0.000131	0.000349	CcSEcCtD
Celecoxib—Tachycardia—Epirubicin—testicular cancer	0.000131	0.000348	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000131	0.000347	CcSEcCtD
Celecoxib—Skin disorder—Epirubicin—testicular cancer	0.00013	0.000346	CcSEcCtD
Celecoxib—Hyperhidrosis—Epirubicin—testicular cancer	0.00013	0.000344	CcSEcCtD
Celecoxib—Insomnia—Methotrexate—testicular cancer	0.00013	0.000344	CcSEcCtD
Celecoxib—Myalgia—Doxorubicin—testicular cancer	0.00013	0.000344	CcSEcCtD
Celecoxib—Arthralgia—Doxorubicin—testicular cancer	0.00013	0.000344	CcSEcCtD
Celecoxib—Chest pain—Doxorubicin—testicular cancer	0.00013	0.000344	CcSEcCtD
Celecoxib—Anxiety—Doxorubicin—testicular cancer	0.000129	0.000343	CcSEcCtD
Celecoxib—Paraesthesia—Methotrexate—testicular cancer	0.000129	0.000342	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000129	0.000341	CcSEcCtD
Celecoxib—Anorexia—Epirubicin—testicular cancer	0.000128	0.00034	CcSEcCtD
Celecoxib—Dyspnoea—Methotrexate—testicular cancer	0.000128	0.000339	CcSEcCtD
Celecoxib—Somnolence—Methotrexate—testicular cancer	0.000128	0.000338	CcSEcCtD
Celecoxib—Dry mouth—Doxorubicin—testicular cancer	0.000127	0.000336	CcSEcCtD
Celecoxib—Dyspepsia—Methotrexate—testicular cancer	0.000126	0.000335	CcSEcCtD
Celecoxib—Confusional state—Doxorubicin—testicular cancer	0.000125	0.000332	CcSEcCtD
Celecoxib—Decreased appetite—Methotrexate—testicular cancer	0.000125	0.000331	CcSEcCtD
Celecoxib—Anaphylactic shock—Doxorubicin—testicular cancer	0.000124	0.00033	CcSEcCtD
Celecoxib—Oedema—Doxorubicin—testicular cancer	0.000124	0.00033	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000124	0.000329	CcSEcCtD
Celecoxib—Fatigue—Methotrexate—testicular cancer	0.000124	0.000328	CcSEcCtD
Celecoxib—Infection—Doxorubicin—testicular cancer	0.000123	0.000327	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000122	0.000325	CcSEcCtD
Celecoxib—Shock—Doxorubicin—testicular cancer	0.000122	0.000324	CcSEcCtD
Celecoxib—Nervous system disorder—Doxorubicin—testicular cancer	0.000122	0.000323	CcSEcCtD
Celecoxib—Thrombocytopenia—Doxorubicin—testicular cancer	0.000122	0.000323	CcSEcCtD
Celecoxib—Insomnia—Epirubicin—testicular cancer	0.000121	0.000322	CcSEcCtD
Celecoxib—Tachycardia—Doxorubicin—testicular cancer	0.000121	0.000322	CcSEcCtD
Celecoxib—Skin disorder—Doxorubicin—testicular cancer	0.000121	0.00032	CcSEcCtD
Celecoxib—Paraesthesia—Epirubicin—testicular cancer	0.000121	0.00032	CcSEcCtD
Celecoxib—Hyperhidrosis—Doxorubicin—testicular cancer	0.00012	0.000319	CcSEcCtD
Celecoxib—Dyspnoea—Epirubicin—testicular cancer	0.00012	0.000318	CcSEcCtD
Celecoxib—Somnolence—Epirubicin—testicular cancer	0.000119	0.000317	CcSEcCtD
Celecoxib—Anorexia—Doxorubicin—testicular cancer	0.000118	0.000314	CcSEcCtD
Celecoxib—PDPK1—Immune System—FGFR3—testicular cancer	0.000118	0.000914	CbGpPWpGaD
Celecoxib—Feeling abnormal—Methotrexate—testicular cancer	0.000118	0.000314	CcSEcCtD
Celecoxib—Dyspepsia—Epirubicin—testicular cancer	0.000118	0.000314	CcSEcCtD
Celecoxib—Gastrointestinal pain—Methotrexate—testicular cancer	0.000117	0.000311	CcSEcCtD
Celecoxib—Decreased appetite—Epirubicin—testicular cancer	0.000117	0.00031	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000116	0.000308	CcSEcCtD
Celecoxib—Fatigue—Epirubicin—testicular cancer	0.000116	0.000307	CcSEcCtD
Celecoxib—Constipation—Epirubicin—testicular cancer	0.000115	0.000305	CcSEcCtD
Celecoxib—CA9—Metabolism—STK11—testicular cancer	0.000115	0.000885	CbGpPWpGaD
Celecoxib—Urticaria—Methotrexate—testicular cancer	0.000114	0.000302	CcSEcCtD
Celecoxib—Body temperature increased—Methotrexate—testicular cancer	0.000113	0.000301	CcSEcCtD
Celecoxib—Abdominal pain—Methotrexate—testicular cancer	0.000113	0.000301	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000113	0.0003	CcSEcCtD
Celecoxib—Insomnia—Doxorubicin—testicular cancer	0.000112	0.000298	CcSEcCtD
Celecoxib—PDPK1—Signaling Pathways—H2AFZ—testicular cancer	0.000112	0.000864	CbGpPWpGaD
Celecoxib—Paraesthesia—Doxorubicin—testicular cancer	0.000112	0.000296	CcSEcCtD
Celecoxib—PDPK1—Signaling Pathways—STK11—testicular cancer	0.000111	0.00086	CbGpPWpGaD
Celecoxib—Dyspnoea—Doxorubicin—testicular cancer	0.000111	0.000294	CcSEcCtD
Celecoxib—Feeling abnormal—Epirubicin—testicular cancer	0.000111	0.000294	CcSEcCtD
Celecoxib—Somnolence—Doxorubicin—testicular cancer	0.00011	0.000293	CcSEcCtD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.00011	0.000853	CbGpPWpGaD
Celecoxib—Gastrointestinal pain—Epirubicin—testicular cancer	0.00011	0.000291	CcSEcCtD
Celecoxib—Dyspepsia—Doxorubicin—testicular cancer	0.000109	0.00029	CcSEcCtD
Celecoxib—PDPK1—Disease—FGFR3—testicular cancer	0.000109	0.000844	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—KIT—testicular cancer	0.000109	0.000839	CbGpPWpGaD
Celecoxib—Decreased appetite—Doxorubicin—testicular cancer	0.000108	0.000287	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000107	0.000285	CcSEcCtD
Celecoxib—Fatigue—Doxorubicin—testicular cancer	0.000107	0.000284	CcSEcCtD
Celecoxib—Urticaria—Epirubicin—testicular cancer	0.000107	0.000283	CcSEcCtD
Celecoxib—Constipation—Doxorubicin—testicular cancer	0.000106	0.000282	CcSEcCtD
Celecoxib—Abdominal pain—Epirubicin—testicular cancer	0.000106	0.000282	CcSEcCtD
Celecoxib—Body temperature increased—Epirubicin—testicular cancer	0.000106	0.000282	CcSEcCtD
Celecoxib—Hypersensitivity—Methotrexate—testicular cancer	0.000106	0.00028	CcSEcCtD
Celecoxib—MAPK14—Innate Immune System—FGFR3—testicular cancer	0.000106	0.000816	CbGpPWpGaD
Celecoxib—Asthenia—Methotrexate—testicular cancer	0.000103	0.000273	CcSEcCtD
Celecoxib—PDPK1—Signaling Pathways—KITLG—testicular cancer	0.000103	0.000795	CbGpPWpGaD
Celecoxib—Feeling abnormal—Doxorubicin—testicular cancer	0.000102	0.000272	CcSEcCtD
Celecoxib—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000102	0.00027	CcSEcCtD
Celecoxib—Pruritus—Methotrexate—testicular cancer	0.000102	0.000269	CcSEcCtD
Celecoxib—PDPK1—Disease—KIT—testicular cancer	0.0001	0.000775	CbGpPWpGaD
Celecoxib—Hypersensitivity—Epirubicin—testicular cancer	9.9e-05	0.000262	CcSEcCtD
Celecoxib—Urticaria—Doxorubicin—testicular cancer	9.87e-05	0.000262	CcSEcCtD
Celecoxib—Abdominal pain—Doxorubicin—testicular cancer	9.83e-05	0.000261	CcSEcCtD
Celecoxib—Body temperature increased—Doxorubicin—testicular cancer	9.83e-05	0.000261	CcSEcCtD
Celecoxib—Diarrhoea—Methotrexate—testicular cancer	9.82e-05	0.00026	CcSEcCtD
Celecoxib—MAPK14—Developmental Biology—MMP2—testicular cancer	9.73e-05	0.000751	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—KIT—testicular cancer	9.7e-05	0.000749	CbGpPWpGaD
Celecoxib—Asthenia—Epirubicin—testicular cancer	9.64e-05	0.000256	CcSEcCtD
Celecoxib—Pruritus—Epirubicin—testicular cancer	9.5e-05	0.000252	CcSEcCtD
Celecoxib—Dizziness—Methotrexate—testicular cancer	9.49e-05	0.000252	CcSEcCtD
Celecoxib—Diarrhoea—Epirubicin—testicular cancer	9.19e-05	0.000244	CcSEcCtD
Celecoxib—Hypersensitivity—Doxorubicin—testicular cancer	9.16e-05	0.000243	CcSEcCtD
Celecoxib—Vomiting—Methotrexate—testicular cancer	9.13e-05	0.000242	CcSEcCtD
Celecoxib—Rash—Methotrexate—testicular cancer	9.05e-05	0.00024	CcSEcCtD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	9.04e-05	0.000698	CbGpPWpGaD
Celecoxib—Dermatitis—Methotrexate—testicular cancer	9.04e-05	0.00024	CcSEcCtD
Celecoxib—Headache—Methotrexate—testicular cancer	8.99e-05	0.000238	CcSEcCtD
Celecoxib—MAPK14—Gene Expression—H2AFZ—testicular cancer	8.95e-05	0.000691	CbGpPWpGaD
Celecoxib—Asthenia—Doxorubicin—testicular cancer	8.92e-05	0.000237	CcSEcCtD
Celecoxib—Dizziness—Epirubicin—testicular cancer	8.88e-05	0.000236	CcSEcCtD
Celecoxib—Pruritus—Doxorubicin—testicular cancer	8.79e-05	0.000233	CcSEcCtD
Celecoxib—Vomiting—Epirubicin—testicular cancer	8.54e-05	0.000227	CcSEcCtD
Celecoxib—Nausea—Methotrexate—testicular cancer	8.53e-05	0.000226	CcSEcCtD
Celecoxib—Diarrhoea—Doxorubicin—testicular cancer	8.5e-05	0.000226	CcSEcCtD
Celecoxib—Rash—Epirubicin—testicular cancer	8.47e-05	0.000225	CcSEcCtD
Celecoxib—Dermatitis—Epirubicin—testicular cancer	8.46e-05	0.000224	CcSEcCtD
Celecoxib—Headache—Epirubicin—testicular cancer	8.41e-05	0.000223	CcSEcCtD
Celecoxib—MAPK14—Immune System—KITLG—testicular cancer	8.28e-05	0.000639	CbGpPWpGaD
Celecoxib—Dizziness—Doxorubicin—testicular cancer	8.22e-05	0.000218	CcSEcCtD
Celecoxib—Nausea—Epirubicin—testicular cancer	7.98e-05	0.000212	CcSEcCtD
Celecoxib—Vomiting—Doxorubicin—testicular cancer	7.9e-05	0.00021	CcSEcCtD
Celecoxib—Rash—Doxorubicin—testicular cancer	7.84e-05	0.000208	CcSEcCtD
Celecoxib—Dermatitis—Doxorubicin—testicular cancer	7.83e-05	0.000208	CcSEcCtD
Celecoxib—Headache—Doxorubicin—testicular cancer	7.79e-05	0.000207	CcSEcCtD
Celecoxib—PDPK1—Signaling Pathways—FGFR3—testicular cancer	7.65e-05	0.000591	CbGpPWpGaD
Celecoxib—Nausea—Doxorubicin—testicular cancer	7.38e-05	0.000196	CcSEcCtD
Celecoxib—PDPK1—Signaling Pathways—KIT—testicular cancer	7.03e-05	0.000543	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—FGFR3—testicular cancer	6.15e-05	0.000475	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—HPGDS—testicular cancer	6.08e-05	0.00047	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—H2AFZ—testicular cancer	5.82e-05	0.000449	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—STK11—testicular cancer	5.78e-05	0.000447	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—KIT—testicular cancer	5.65e-05	0.000436	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—KITLG—testicular cancer	5.35e-05	0.000413	CbGpPWpGaD
Celecoxib—PTGS2—Disease—H2AFZ—testicular cancer	5.31e-05	0.00041	CbGpPWpGaD
Celecoxib—ALB—Metabolism—HPGDS—testicular cancer	4.92e-05	0.00038	CbGpPWpGaD
Celecoxib—PTGS2—Disease—KITLG—testicular cancer	4.88e-05	0.000377	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—STK11—testicular cancer	4.42e-05	0.000341	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—HPGDS—testicular cancer	4.06e-05	0.000314	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—HPGDS—testicular cancer	4.03e-05	0.000311	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—FGFR3—testicular cancer	3.98e-05	0.000307	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—KIT—testicular cancer	3.65e-05	0.000282	CbGpPWpGaD
Celecoxib—PTGS2—Disease—FGFR3—testicular cancer	3.63e-05	0.00028	CbGpPWpGaD
Celecoxib—ALB—Metabolism—STK11—testicular cancer	3.57e-05	0.000276	CbGpPWpGaD
Celecoxib—PTGS2—Disease—KIT—testicular cancer	3.33e-05	0.000257	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—STK11—testicular cancer	2.95e-05	0.000228	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—STK11—testicular cancer	2.93e-05	0.000226	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—HPGDS—testicular cancer	2.66e-05	0.000205	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—STK11—testicular cancer	1.93e-05	0.000149	CbGpPWpGaD
